# OnCo record paper-erivance-vismodegib-sekulic-nejm-2012 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-erivance-vismodegib-sekulic-nejm-2012/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-erivance-vismodegib-sekulic-nejm-2012" ;
  schema:name "ERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma"@en ;
  schema:description "The hedgehog pathway inhibitor vismodegib shrank tumours in 43 percent of patients with locally advanced and 30 percent with metastatic basal cell carcinoma, becoming the first drug approved for advanced basal cell carcinoma."@en ;
  schema:url <https://onco.cc/key-papers/paper-erivance-vismodegib-sekulic-nejm-2012/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1113713>, <https://pubmed.ncbi.nlm.nih.gov/22670903/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1113713> ;
  schema:datePublished "2012"^^xsd:gYear ;
  schema:author "Sekulic A, Migden MR, Oro AE, et al." ;
  onco:cancers <https://onco.cc/cancers/locally-advanced-bcc/> ;
  onco:drugs <https://onco.cc/drugs/vismodegib/> ;
  onco:trials <https://onco.cc/trials/erivance/> ;
  onco:journals <https://onco.cc/journals/nejm/> .